Last reviewed · How we verify

NCT04308551

Effect of Indobufen and Aspirin on Platelet Aggregation and Long Term Prognosis in Patients With Coronary Heart Disease

Withdrawn NA Last updated 20 November 2024
What this trial tests

NA trial testing Indobufen in Stable Coronary Heart Disease. Withdrawn.

Timeline
30 December 2024
Primary endpoint
30 December 2026
30 December 2026

Quick facts

Lead sponsorHenan Institute of Cardiovascular Epidemiology
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposeother
Start date30 December 2024
Primary completion30 December 2026
Estimated completion30 December 2026

Drugs / interventions tested

Conditions studied

Sponsor

Henan Institute of Cardiovascular Epidemiology

Who can join

Adults 18 to 85, any sex, with Stable Coronary Heart Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the effect of Indobufen and Aspirin on platelet aggregation and long term prognosis in patients with stable coronary heart disease.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Indobufen

Trials testing the same drug.

Other Henan Institute of Cardiovascular Epidemiology trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04308551.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing